Submitted:
18 June 2026
Posted:
22 June 2026
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results and Discussion
2.1. Intrinsic Disorder Status of Human TBI-Related Proteins
2.2. Disorder-Based Functionality and LLPS Potential of the 24 Human TBI-Related Proteins
2.2.1. Looking at the LLPS Potential
2.2.2. Small EDRK-Rich Factor 2 (SERF2; UniProt ID: P84101; ADSVSL2 = 0.9906; PPIDRVSL2 = 100.00%; pLLPS = 0.9942)
2.2.3. Fused in Sarcoma (FUS, UniProt ID: P35637; ADSVSL2 = 0.8894; PPIDRVSL2 = 90.68%; pLLPS = 0.9999)
2.2.4. Microtubule-Associated Protein tau (MAPT; UniProt ID: P10636; ADSVSL2 = 0.8580; PPIDRVSL2 = 99.08%; pLLPS = 0.9985)
2.2.5. High Mobility Group Protein B1 (HMGB1; UniProt ID: P09429; ADSVSL2 = 0.8511; PPIDRVSL2 = 91.16%; pLLPS = 0.8945)
2.2.6. SERPINE1 mRNA-Binding Protein 1 (SERBP1; UniProt ID: Q8NC51; ADSVSL2 = 0.8413; PPIDRVSL2 = 96.32%; pLLPS = 0.9972)
2.2.7. Neurofilament Medium Polypeptide (NEFM; UniProt ID: P07197; ADSVSL2 = 0.8292; PPIDRVSL2 = 88.32%; pLLPS = 0.9977)
2.2.8. Brain-Expressed X-Linked Protein 3 (BEX3; UniProt ID: Q00994; ADSVSL2 = 0.8194; PPIDRVSL2 = 100.00%; pLLPS = 0.9751)
2.2.9. C9orf16; Bublin Coiled-Coil Protein (BBLN; UniProt ID: Q9BUW7; ADSVSL2 = 0.7337; PPIDRVSL2 = 84.34%; pLLPS = 0.9307)
2.2.10. Hematopoietic Lineage Cell-Specific Protein (HCLS1; UniProt ID: P14317; ADSVSL2 = 0.7326; PPIDRVSL2 = 87.45%; pLLPS = 0.9967)
2.2.11. Ras/Rap GTPase-Activating Protein SynGAP (SYNGAP1; UniProt ID: Q96PV0; ADSVSL2 = 0.6640; PPIDRVSL2 = 66.34%; pLLPS = 0.9886)
2.2.12. Analysis of the Global Interactivity of TBIome
3. Materials and Methods
3.1. Protein Selection
- Compelling evidence of being characterized as intrinsically disordered proteins;
- Interplay of the roles in neurodegeneration, neuroinflammation, and axonal damage caused by the TBI;
- Relevance to TBI and clinical approval of acting as a tissue biomarker.
3.2. Bioinformatic Analysis
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
| AD | Alzheimer’s disease |
| ADS | Average disorder acore |
| AI | Artificial intelligence |
| AIF1L | Allograft inflammatory factor 1-like |
| ALS | Amyotrophic lateral sclerosis |
| APOC2 | Apolipoprotein C-II |
| APP | Amyloid precursor protein |
| BBLN | Bublin coiled-coil protein |
| BEX3 | Brain-expressed X-linked protein 3 |
| CAMK2A | Calcium/calmodulin-dependent protein kinase type II subunit alpha |
| CNS | Central nervous system |
| DLG4 | Disks large homolog 4 |
| EPHA4 | Ephrin type-A receptor |
| FUS | RNA-binding protein FUS |
| GO | Gene ontology |
| HCLS1 | Hematopoietic cell-specific Lyn substrate 1 |
| HD | Huntington’s disease |
| HMGB1 | High mobility group protein B1 |
| IDP | Intrinsically disordered protein |
| IDR | Intrinsically disordered region |
| LLPS | Liquid-liquid phase separation |
| MAPT | Microtubule-associated protein tau |
| MOAG4 | Modifier of aggregation 4 |
| MoRF | Molecular recognition feature |
| NEFL | Neurofilament light chain |
| NEFM | Neurofilament medium polypeptide |
| NRN1 | Neuritin |
| PD | Parkinson’s disease |
| PET | Positron emission tomography |
| PLEK | Pleckstrin |
| PPI | Protein-protein interaction |
| PPIDR | Percent of predicted intrinsically disordered residues |
| PSD | Postsynaptic density |
| S100B | S100 calcium-binding protein B |
| SEMA4D | Semaphorin-4D |
| SERBP1 | SERPINE1 mRNA-binding protein 1 |
| SERF2 | Small EDRK-rich factor 2 |
| SNAP25 | Synaptosomal-associated protein 25 |
| SNCA | α-Synuclein |
| SYNGAP1 | Ras/Rap GTPase-activating protein SynGAP |
| TBI | Traumatic brain injury |
| TBIome | TBI-related proteins |
| TDP43 | TAR DNA-binding protein 43 |
References
- Tzara, O. Identification and Exploration of Neuronal Protein Fragments in Serum ad Biomarkers for Neurodegenerative Diseases; Technical University of Denmark: Lyngby, Denmark, 2020. [Google Scholar]
- Orr, T.J.; Lesha, E.; Kramer, A.H.; Cecia, A.; Dugan, J.E.; Schwartz, B.; Einhaus, S.L. Traumatic Brain Injury: A Comprehensive Review of Biomechanics and Molecular Pathophysiology. World Neurosurg. 2024, 185, 74–88. [Google Scholar] [CrossRef] [PubMed]
- Taylor, C.A.; Bell, J.M.; Breiding, M.J.; Xu, L. Traumatic Brain Injury-Related Emergency Department Visits, Hospitalizations, and Deaths - United States, 2007 and 2013. MMWR Surveill. Summ. 2017, 66, 1–16. [Google Scholar] [CrossRef] [PubMed]
- CDC. TBI Data. 2026. [Google Scholar] [CrossRef]
- WISQARS. CDC WISQARS - Injury Data Reports. 2026. [Google Scholar] [PubMed]
- Tu, F.; Wu, W.; Yin, S.; Liu, L.; Wei, S. RANA: Towards efficient neural acceleration with refresh-optimized embedded DRAM. In Proceedings of the 2018 ACM/IEEE 45th Annual International Symposium on Computer Architecture (ISCA), 2018; pp. 340–352. [Google Scholar]
- Yue, J.K.; Kobeissy, F.H.; Jain, S.; Sun, X.; Phelps, R.R.L.; Korley, F.K.; Gardner, R.C.; Ferguson, A.R.; Huie, J.R.; Schneider, A.L.C.; et al. Neuroinflammatory Biomarkers for Traumatic Brain Injury Diagnosis and Prognosis: A TRACK-TBI Pilot Study. Neurotrauma Rep. 2023, 4, 171–183. [Google Scholar] [CrossRef] [PubMed]
- Khellaf, A.; Khan, D.Z.; Helmy, A. Recent advances in traumatic brain injury. J. Neurol. 2019, 266, 2878–2889. [Google Scholar] [CrossRef] [PubMed]
- Balakin, E.; Yurku, K.; Fomina, T.; Butkova, T.; Nakhod, V.; Izotov, A.; Kaysheva, A.; Pustovoyt, V. A Systematic Review of Traumatic Brain Injury in Modern Rodent Models: Current Status and Future Prospects. Biology 2024, 13. [Google Scholar] [CrossRef] [PubMed]
- Freire, M.A.M.; Rocha, G.S.; Bittencourt, L.O.; Falcao, D.; Lima, R.R.; Cavalcanti, J. Cellular and Molecular Pathophysiology of Traumatic Brain Injury: What Have We Learned So Far? Biology 2023, 12. [Google Scholar] [CrossRef] [PubMed]
- Kokiko-Cochran, O.; Ransohoff, L.; Veenstra, M.; Lee, S.; Saber, M.; Sikora, M.; Teknipp, R.; Xu, G.; Bemiller, S.; Wilson, G.; et al. Altered Neuroinflammation and Behavior after Traumatic Brain Injury in a Mouse Model of Alzheimer’s Disease. J. Neurotrauma 2016, 33, 625–640. [Google Scholar] [CrossRef] [PubMed]
- Muller, L.; Di Benedetto, S.; Muller, V. The dual nature of neuroinflammation in networked brain. Front Immunol. 2025, 16, 1659947. [Google Scholar] [CrossRef] [PubMed]
- Fornari Laurindo, L.; Aparecido Dias, J.; Cressoni Araujo, A.; Torres Pomini, K.; Machado Galhardi, C.; Rucco Penteado Detregiachi, C.; Santos de Argollo Haber, L.; Donizeti Roque, D.; Dib Bechara, M.; Vialogo Marques de Castro, M.; et al. Immunological dimensions of neuroinflammation and microglial activation: exploring innovative immunomodulatory approaches to mitigate neuroinflammatory progression. Front Immunol. 2023, 14, 1305933. [Google Scholar] [CrossRef] [PubMed]
- Kamila, P.; Kar, K.; Chowdhury, S.; Chakraborty, P.; Dutta, R.; S, S.; Singh, S.A.; Prajapati, B.G. Effect of neuroinflammation on the progression of Alzheimer’s disease and its significant ramifications for novel anti-inflammatory treatments. IBRO Neurosci. Rep. 2025, 18, 771–782. [Google Scholar] [CrossRef] [PubMed]
- Kolliker-Frers, R.; Udovin, L.; Otero-Losada, M.; Kobiec, T.; Herrera, M.I.; Palacios, J.; Razzitte, G.; Capani, F. Neuroinflammation: An Integrating Overview of Reactive-Neuroimmune Cell Interactions in Health and Disease. Mediat. Inflamm. 2021, 2021, 9999146. [Google Scholar] [CrossRef] [PubMed]
- Balistreri, C. Is the Myasthenia Gravis (MG) the Result of Age and Sex/Gender? A Narrative Review for Identifying Genetic and Epigenetic Biomarkers for a Differential MG Management in Old and Young Women. Preprints 2024, 2024041538. [Google Scholar] [CrossRef]
- Zhang, W.; Xiao, D.; Mao, Q.; Xia, H. Role of neuroinflammation in neurodegeneration development. Signal Transduct. Target Ther. 2023, 8, 267. [Google Scholar] [CrossRef] [PubMed]
- Adamu, A.; Li, S.; Gao, F.; Xue, G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024, 16, 1347987. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N. Dancing Protein Clouds: The Strange Biology and Chaotic Physics of Intrinsically Disordered Proteins. J. Biol. Chem. 2016, 291, 6681–6688. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N. Protein intrinsic disorder and structure-function continuum. Prog. Mol. Biol. Transl. Sci. 2019, 166, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Gupta, M.N.; Uversky, V.N. Protein structure-function continuum model: Emerging nexuses between specificity, evolution, and structure. Protein Sci. 2024, 33, e4968. [Google Scholar] [CrossRef] [PubMed]
- Trivedi, R.; Nagarajaram, H.A. Intrinsically Disordered Proteins: An Overview. Int. J. Mol. Sci. 2022, 23. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.; Huang, Y. Advantages of proteins being disordered. Protein Sci. 2014, 23, 539–550. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N. Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 2002, 11, 739–756. [Google Scholar] [CrossRef] [PubMed]
- Lermyte, F. Roles, Characteristics, and Analysis of Intrinsically Disordered Proteins: A Minireview. Life 2020, 10. [Google Scholar] [CrossRef] [PubMed]
- Gsponer, J.; Futschik, M.E.; Teichmann, S.A.; Babu, M.M. Tight regulation of unstructured proteins: from transcript synthesis to protein degradation. Science 2008, 322, 1365–1368. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N.; Dunker, A.K. Biochemistry. Controlled chaos. Science 2008, 322, 1340–1341. [Google Scholar] [CrossRef] [PubMed]
- Trivedi, R.; Nagarajaram, H.A. Amino acid substitution scoring matrices specific to intrinsically disordered regions in proteins. Sci. Rep. 2019, 9, 16380. [Google Scholar] [CrossRef] [PubMed]
- Brown, C.J.; Johnson, A.K.; Daughdrill, G.W. Comparing models of evolution for ordered and disordered proteins. Mol. Biol. Evol. 2010, 27, 609–621. [Google Scholar] [CrossRef] [PubMed]
- He, B.; Wang, K.; Liu, Y.; Xue, B.; Uversky, V.N.; Dunker, A.K. Predicting intrinsic disorder in proteins: an overview. Cell Res. 2009, 19, 929–949. [Google Scholar] [CrossRef] [PubMed]
- Dosztanyi, Z.; Meszaros, B.; Simon, I. Bioinformatical approaches to characterize intrinsically disordered/unstructured proteins. Brief. Bioinform. 2010, 11, 225–243. [Google Scholar] [CrossRef] [PubMed]
- Mizianty, M.J.; Zhang, T.; Xue, B.; Zhou, Y.; Dunker, A.K.; Uversky, V.N.; Kurgan, L. In-silico prediction of disorder content using hybrid sequence representation. BMC Bioinform. 2011, 12, 245. [Google Scholar] [CrossRef] [PubMed]
- van der Lee, R.; Buljan, M.; Lang, B.; Weatheritt, R.J.; Daughdrill, G.W.; Dunker, A.K.; Fuxreiter, M.; Gough, J.; Gsponer, J.; Jones, D.T.; et al. Classification of intrinsically disordered regions and proteins. Chem. Rev. 2014, 114, 6589–6631. [Google Scholar] [CrossRef] [PubMed]
- Meng, F.; Uversky, V.; Kurgan, L. Computational Prediction of Intrinsic Disorder in Proteins. Curr. Protoc. Protein Sci. 2017, 88, 2 16 11–12 16 14. [Google Scholar] [CrossRef] [PubMed]
- Roterman, I.; Stapor, K.; Fabian, P.; Konieczny, L. In Silico Modeling of the Influence of Environment on Amyloid Folding Using FOD-M Model. Int. J. Mol. Sci. 2021, 22. [Google Scholar] [CrossRef] [PubMed]
- Kahriman, A.; Bouley, J.; Smith, T.W.; Bosco, D.A.; Woerman, A.L.; Henninger, N. Mouse closed head traumatic brain injury replicates the histological tau pathology pattern of human disease: characterization of a novel model and systematic review of the literature. Acta Neuropathol. Commun. 2021, 9, 118. [Google Scholar] [CrossRef] [PubMed]
- Delic, V.; Beck, K.D.; Pang, K.C.H.; Citron, B.A. Biological links between traumatic brain injury and Parkinson’s disease. Acta Neuropathol. Commun. 2020, 8, 45. [Google Scholar] [CrossRef] [PubMed]
- Ayala, Y.M.; De Conti, L.; Avendano-Vazquez, S.E.; Dhir, A.; Romano, M.; D’Ambrogio, A.; Tollervey, J.; Ule, J.; Baralle, M.; Buratti, E.; et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011, 30, 277–288. [Google Scholar] [CrossRef] [PubMed]
- Edwards, G., 3rd; Zhao, J.; Dash, P.K.; Soto, C.; Moreno-Gonzalez, I. Traumatic Brain Injury Induces Tau Aggregation and Spreading. J. Neurotrauma 2020, 37, 80–92. [Google Scholar] [CrossRef] [PubMed]
- Kawai, N.; Kawanishi, M.; Kudomi, N.; Maeda, Y.; Yamamoto, Y.; Nishiyama, Y.; Tamiya, T. Detection of brain amyloid beta deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh Compound-B. Brain Inj. 2013, 27, 1026–1031. [Google Scholar] [CrossRef] [PubMed]
- Schneider, A.L.C.; Selvin, E.; Liang, M.; Latour, L.; Turtzo, L.C.; Koton, S.; Coresh, J.; Mosley, T.; Whitlow, C.T.; Zhou, Y.; et al. Association of Head Injury with Brain Amyloid Deposition: The ARIC-PET Study. J. Neurotrauma 2019, 36, 2549–2557. [Google Scholar] [CrossRef] [PubMed]
- Hicks, A.J.; Ponsford, J.L.; Spitz, G.; Dore, V.; Krishnadas, N.; Roberts, C.; Rowe, C.C. beta-Amyloid and Tau Imaging in Chronic Traumatic Brain Injury: A Cross-sectional Study. Neurology 2022, 99, e1131–e1141. [Google Scholar] [CrossRef] [PubMed]
- Turk, K.W.; Geada, A.; Alvarez, V.E.; Xia, W.; Cherry, J.D.; Nicks, R.; Meng, G.; Daley, S.; Tripodis, Y.; Huber, B.R.; et al. A comparison between tau and amyloid-beta cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease. Alzheimers Res. Ther. 2022, 14, 28. [Google Scholar] [CrossRef] [PubMed]
- Thelin, E.P.; Zeiler, F.A.; Ercole, A.; Mondello, S.; Buki, A.; Bellander, B.M.; Helmy, A.; Menon, D.K.; Nelson, D.W. Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review. Front Neurol. 2017, 8, 300. [Google Scholar] [CrossRef] [PubMed]
- Paudel, Y.N.; Angelopoulou, E.; Piperi, C.; Othman, I.; Shaikh, M.F. HMGB1-Mediated Neuroinflammatory Responses in Brain Injuries: Potential Mechanisms and Therapeutic Opportunities. Int. J. Mol. Sci. 2020, 21. [Google Scholar] [CrossRef] [PubMed]
- Ngadimon, I.W.; Mohan, D.; Shaikh, M.F.; Khoo, C.S.; Tan, H.J.; Lee, Y.M.; Chamhuri, N.S.; Fadzil, F.; Zolkafli, N.; Arulsamy, A.; et al. HMGB1 blood levels and neurological outcomes after traumatic brain injury: Insights from an exploratory study. Epilepsia Open 2025, 10, 494–507. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.Q.; Gao, S.Q.; Luo, L.; Jiang, Z.Y.; Liang, C.F.; He, H.Y.; Guo, Y. Nonoxid-HMGB1 Attenuates Cognitive Impairment After Traumatic Brain Injury in Rats. Front Med. 2022, 9, 827585. [Google Scholar] [CrossRef] [PubMed]
- Di Pietro, V.; Amorini, A.M.; Lazzarino, G.; Yakoub, K.M.; D’Urso, S.; Lazzarino, G.; Belli, A. S100B and Glial Fibrillary Acidic Protein as Indexes to Monitor Damage Severity in an In Vitro Model of Traumatic Brain Injury. Neurochem Res. 2015, 40, 991–999. [Google Scholar] [CrossRef] [PubMed]
- Guerrero, E.N.; Wang, H.; Mitra, J.; Hegde, P.M.; Stowell, S.E.; Liachko, N.F.; Kraemer, B.C.; Garruto, R.M.; Rao, K.S.; Hegde, M.L. TDP-43/FUS in motor neuron disease: Complexity and challenges. Prog. Neurobiol. 2016, 145-146, 78–97. [Google Scholar] [CrossRef] [PubMed]
- Wiesner, D.; Tar, L.; Linkus, B.; Chandrasekar, A.; Olde Heuvel, F.; Dupuis, L.; Tsao, W.; Wong, P.C.; Ludolph, A.; Roselli, F. Reversible induction of TDP-43 granules in cortical neurons after traumatic injury. Exp. Neurol. 2018, 299, 15–25. [Google Scholar] [CrossRef] [PubMed]
- Acosta, S.A.; Tajiri, N.; de la Pena, I.; Bastawrous, M.; Sanberg, P.R.; Kaneko, Y.; Borlongan, C.V. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson’s disease. J. Cell Physiol. 2015, 230, 1024–1032. [Google Scholar] [CrossRef] [PubMed]
- Yoshiyama, Y.; Uryu, K.; Higuchi, M.; Longhi, L.; Hoover, R.; Fujimoto, S.; McIntosh, T.; Lee, V.M.; Trojanowski, J.Q. Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model. J. Neurotrauma 2005, 22, 1134–1141. [Google Scholar] [CrossRef] [PubMed]
- Tan, Y.; Xia, J.; Liu, M.; Deng, S.; Wu, H.; Qian, C. After Traumatic Brain Injury, EPHA4 Enhances Endoplasmic Reticulum Stress to Promote M1 Microglial Polarization Through the MAPK Signaling Pathway. Mediat. Inflamm. 2026, 2026, 5595023. [Google Scholar] [CrossRef] [PubMed]
- Wei, H.X.; Guan, Y.N.; Chen, P.P.; Rao, Z.Z.; Yang, J.S. Upregulation of EphA4 deteriorate brain damage by shifting microglia M1-polarization via NF-kappaB signaling after focal cerebral ischemia in rats. Heliyon 2023, 9, e18429. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Zhong, Y.; Xie, X.; Jiang, G.; Bai, L.; Li, H.; Li, X.; Wang, X.; Chen, G. VASP, HCLS1, MSN, and EZR: Key molecular beacons in the pathophysiology of perihematomal edema Post-Intracerebral hemorrhage. Brain Hemorrhages 2024, 5, 223–232. [Google Scholar] [CrossRef]
- Moreau-Fauvarque, C.; Kumanogoh, A.; Camand, E.; Jaillard, C.; Barbin, G.; Boquet, I.; Love, C.; Jones, E.Y.; Kikutani, H.; Lubetzki, C.; et al. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J. Neurosci. 2003, 23, 9229–9239. [Google Scholar] [CrossRef] [PubMed]
- Evans, E.E.; Mishra, V.; Mallow, C.; Gersz, E.M.; Balch, L.; Howell, A.; Reilly, C.; Smith, E.S.; Fisher, T.L.; Zauderer, M. Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity. J. Neuroinflammation 2022, 19, 200. [Google Scholar] [CrossRef] [PubMed]
- Shultz, S.R.; Shah, A.D.; Huang, C.; Dill, L.K.; Schittenhelm, R.B.; Morganti-Kossmann, M.C.; Semple, B.D. Temporal proteomics of human cerebrospinal fluid after severe traumatic brain injury. J. Neuroinflammation 2022, 19, 291. [Google Scholar] [CrossRef] [PubMed]
- Ponten, F.; Jirstrom, K.; Uhlen, M. The Human Protein Atlas--a tool for pathology. J. Pathol. 2008, 216, 387–393. [Google Scholar] [CrossRef] [PubMed]
- Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; et al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 2010, 28, 1248–1250. [Google Scholar] [CrossRef] [PubMed]
- Uhlen, M.; Fagerberg, L.; Hallstrom, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, A.; Kampf, C.; Sjostedt, E.; Asplund, A.; et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347, 1260419. [Google Scholar] [CrossRef] [PubMed]
- Sjostedt, E.; Zhong, W.; Fagerberg, L.; Karlsson, M.; Mitsios, N.; Adori, C.; Oksvold, P.; Edfors, F.; Limiszewska, A.; Hikmet, F.; et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science 2020, 367. [Google Scholar] [CrossRef] [PubMed]
- Pritisanac, I.; Alderson, T.R.; Kolaric, D.; Zarin, T.; Xie, S.; Lu, A.; Alam, A.; Maqsood, A.; Youn, J.Y.; Forman-Kay, J.D.; et al. A functional map of the human intrinsically disordered proteome. Proc. Natl. Acad. Sci. U S A 2026, 123, e2604562123. [Google Scholar] [CrossRef] [PubMed]
- Mohammed, A.S.; Uversky, V.N. Intrinsic Disorder as a Natural Preservative: High Levels of Intrinsic Disorder in Proteins Found in the 2600-Year-Old Human Brain. Biology 2022, 11. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N. Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept. Expert Rev. Proteom. 2010, 7, 543–564. [Google Scholar] [CrossRef] [PubMed]
- Mantash, S.; Aboulouard, S.; Dakik, H.; Zirem, Y.; Ziane-Chaouche, L.; Nehme, A.; Mallah, K.; El-Kurdi, M.; Ramadan, N.; Fournier, I.; et al. Uncovering injury-specific proteomic signatures and neurodegenerative risks in single and repetitive traumatic brain injury. Signal Transduct. Target Ther. 2025, 10, 195. [Google Scholar] [CrossRef] [PubMed]
- Brett, B.L.; Gardner, R.C.; Godbout, J.; Dams-O’Connor, K.; Keene, C.D. Traumatic Brain Injury and Risk of Neurodegenerative Disorder. Biol. Psychiatry 2022, 91, 498–507. [Google Scholar] [CrossRef] [PubMed]
- Sowers, J.L.; Wu, P.; Zhang, K.; DeWitt, D.S.; Prough, D.S. Proteomic changes in traumatic brain injury: experimental approaches. Curr. Opin. Neurol. 2018, 31, 709–717. [Google Scholar] [CrossRef] [PubMed]
- Abramson, J.; Adler, J.; Dunger, J.; Evans, R.; Green, T.; Pritzel, A.; Ronneberger, O.; Willmore, L.; Ballard, A.J.; Bambrick, J.; et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 2024, 630, 493–500. [Google Scholar] [CrossRef] [PubMed]
- Sun, Y.; Sheng, D.; Zhou, Z.; Wu, Y. AI hallucination: towards a comprehensive classification of distorted information in artificial intelligence-generated content. Humanit. Soc. Sci. Commun. 2024, 11, 1–14. [Google Scholar] [CrossRef]
- Ji, Z.; Lee, N.; Frieske, R.; Yu, T.; Su, D.; Xu, Y.; Ishii, E.; Bang, Y.J.; Madotto, A.; Fung, P. Survey of hallucination in natural language generation. ACM Comput. Surv. 2023, 55, 1–38. [Google Scholar] [CrossRef]
- Rathkopf, C. Hallucination, reliability, and the role of generative AI in science. arXiv 2025, arXiv:2504.08526. [Google Scholar]
- Madaj, R.; Martinez-Goikoetxea, M.; Kaminski, K.; Ludwiczak, J.; Dunin-Horkawicz, S. Applicability of AlphaFold2 in the modeling of dimeric, trimeric, and tetrameric coiled-coil domains. Protein Sci. 2025, 34, e5244. [Google Scholar] [PubMed]
- Zhang, J.; Xue, G.; Wang, X.; Rao, X.; Chen, J.; Fan, L.; Liu, L.; Gan, J. Research progress in SYNGAP1-related neurodevelopmental disorders: from pathogenesis to therapeutic strategies. Front Neurol. 2026, 17, 1773363. [Google Scholar] [CrossRef] [PubMed]
- Gao, J.; Pang, X.; Zhang, L.; Li, S.; Qin, Z.; Xie, X.; Liu, J. Transcriptome analysis reveals the neuroprotective effect of Dlg4 against fastigial nucleus stimulation-induced ischemia/reperfusion injury in rats. BMC Neurosci. 2023, 24, 40. [Google Scholar] [CrossRef] [PubMed]
- Meili, F.; Wei, W.J.; Sin, W.C.; Meyers, W.M.; Dascalu, I.; Callaghan, D.B.; Rogic, S.; Pavlidis, P.; Haas, K. Multi-parametric analysis of 57 SYNGAP1 variants reveal impacts on GTPase signaling, localization, and protein stability. Am. J. Hum. Genet 2021, 108, 148–162. [Google Scholar] [CrossRef] [PubMed]
- van Ham, T.J.; Holmberg, M.A.; van der Goot, A.T.; Teuling, E.; Garcia-Arencibia, M.; Kim, H.E.; Du, D.; Thijssen, K.L.; Wiersma, M.; Burggraaff, R.; et al. Identification of MOAG-4/SERF as a regulator of age-related proteotoxicity. Cell 2010, 142, 601–612. [Google Scholar] [CrossRef] [PubMed]
- Pras, A.; Houben, B.; Aprile, F.A.; Seinstra, R.; Gallardo, R.; Janssen, L.; Hogewerf, W.; Gallrein, C.; De Vleeschouwer, M.; Mata-Cabana, A.; et al. The cellular modifier MOAG-4/SERF drives amyloid formation through charge complementation. EMBO J. 2021, 40, e107568. [Google Scholar] [CrossRef] [PubMed]
- Balasubramaniam, M.; Ayyadevara, S.; Shmookler Reis, R.J. Structural insights into pro-aggregation effects of C. elegans CRAM-1 and its human ortholog SERF2. Sci. Rep. 2018, 8, 14891. [Google Scholar] [CrossRef] [PubMed]
- Sahoo, B.R.; Deng, X.; Wong, E.L.; Clark, N.; Yang, H.J.; Kovalenko, A.; Subramanian, V.; Guzman, B.B.; Harris, S.E.; Dehury, B.; et al. Visualization of liquid-liquid phase transitions using a tiny G-quadruplex binding protein. Nat. Commun. 2025, 16, 8578. [Google Scholar] [CrossRef] [PubMed]
- Sahoo, B.R.; Subramanian, V.; Bardwell, J.C.A. Backbone 1H, 13C, and 15N chemical shift assignments for human SERF2. Biomol. NMR Assign. 2024, 18, 51–57. [Google Scholar] [CrossRef] [PubMed]
- Lagier-Tourenne, C.; Polymenidou, M.; Cleveland, D.W. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet 2010, 19, R46–64. [Google Scholar] [CrossRef] [PubMed]
- Conlon, E.G.; Manley, J.L. RNA-binding proteins in neurodegeneration: mechanisms in aggregate. Genes Dev. 2017, 31, 1509–1528. [Google Scholar] [CrossRef] [PubMed]
- Patel, A.; Lee, H.O.; Jawerth, L.; Maharana, S.; Jahnel, M.; Hein, M.Y.; Stoynov, S.; Mahamid, J.; Saha, S.; Franzmann, T.M.; et al. A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell 2015, 162, 1066–1077. [Google Scholar] [CrossRef] [PubMed]
- Mietelska-Porowska, A.; Wasik, U.; Goras, M.; Filipek, A.; Niewiadomska, G. Tau protein modifications and interactions: their role in function and dysfunction. Int. J. Mol. Sci. 2014, 15, 4671–4713. [Google Scholar] [CrossRef] [PubMed]
- Drechsel, D.N.; Hyman, A.A.; Cobb, M.H.; Kirschner, M.W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3, 1141–1154. [Google Scholar] [CrossRef] [PubMed]
- Shi, Y.; Yamada, K.; Liddelow, S.A.; Smith, S.T.; Zhao, L.; Luo, W.; Tsai, R.M.; Spina, S.; Grinberg, L.T.; Rojas, J.C.; et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 2017, 549, 523–527. [Google Scholar] [CrossRef] [PubMed]
- Venkatramani, A.; Panda, D. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies. Int. J. Biol. Macromol. 2019, 133, 473–483. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Lin, Y.; Eschmann, N.A.; Zhou, H.; Rauch, J.N.; Hernandez, I.; Guzman, E.; Kosik, K.S.; Han, S. RNA stores tau reversibly in complex coacervates. PLoS Biol. 2017, 15, e2002183. [Google Scholar] [CrossRef] [PubMed]
- Ambadipudi, S.; Biernat, J.; Riedel, D.; Mandelkow, E.; Zweckstetter, M. Liquid-liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau. Nat. Commun. 2017, 8, 275. [Google Scholar] [CrossRef] [PubMed]
- Wegmann, S.; Eftekharzadeh, B.; Tepper, K.; Zoltowska, K.M.; Bennett, R.E.; Dujardin, S.; Laskowski, P.R.; MacKenzie, D.; Kamath, T.; Commins, C.; et al. Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J. 2018, 37. [Google Scholar] [CrossRef] [PubMed]
- Ferreon, J.C.; Jain, A.; Choi, K.J.; Tsoi, P.S.; MacKenzie, K.R.; Jung, S.Y.; Ferreon, A.C. Acetylation Disfavors Tau Phase Separation. Int. J. Mol. Sci. 2018, 19. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.; McCarty, J.; Rauch, J.N.; Delaney, K.T.; Kosik, K.S.; Fredrickson, G.H.; Shea, J.E.; Han, S. Narrow equilibrium window for complex coacervation of tau and RNA under cellular conditions. Elife 2019, 8. [Google Scholar] [CrossRef] [PubMed]
- Boyko, S.; Qi, X.; Chen, T.H.; Surewicz, K.; Surewicz, W.K. Liquid-liquid phase separation of tau protein: The crucial role of electrostatic interactions. J. Biol. Chem. 2019, 294, 11054–11059. [Google Scholar] [CrossRef] [PubMed]
- Ambadipudi, S.; Reddy, J.G.; Biernat, J.; Mandelkow, E.; Zweckstetter, M. Residue-specific identification of phase separation hot spots of Alzheimer’s-related protein tau. Chem. Sci. 2019, 10, 6503–6507. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.; Wang, H.; Chavan, S.S.; Andersson, U. High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule. Mol. Med. 2015, 21 Suppl 1, S6–S12. [Google Scholar] [CrossRef] [PubMed]
- Martinotti, S.; Patrone, M.; Ranzato, E. Emerging roles for HMGB1 protein in immunity, inflammation, and cancer. Immunotargets Ther. 2015, 4, 101–109. [Google Scholar] [CrossRef] [PubMed]
- Taverna, S.; Tonacci, A.; Ferraro, M.; Cammarata, G.; Cuttitta, G.; Bucchieri, S.; Pace, E.; Gangemi, S. High Mobility Group Box 1: Biological Functions and Relevance in Oxidative Stress Related Chronic Diseases. Cells 2022, 11. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Wang, L.; Hu, F.; Zou, M.; Luo, R.; Sun, Y.; Wang, T.; Guo, Q.; Peng, X. Extracellular HMGB1 as Inflammatory Mediator in the Progression of Mycoplasma Gallisepticum Infection. Cells 2022, 11. [Google Scholar] [CrossRef] [PubMed]
- Datta, S.; Rahman, M.A.; Koka, S.; Boini, K.M. High Mobility Group Box 1 (HMGB1): Molecular Signaling and Potential Therapeutic Strategies. Cells 2024, 13. [Google Scholar] [CrossRef] [PubMed]
- Bianchi, M.E. HMGB1 loves company. J. Leukoc. Biol. 2009, 86, 573–576. [Google Scholar] [CrossRef] [PubMed]
- Strom, A.R.; Emelyanov, A.V.; Mir, M.; Fyodorov, D.V.; Darzacq, X.; Karpen, G.H. Phase separation drives heterochromatin domain formation. Nature 2017, 547, 241–245. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.; Wang, H.; Andersson, U. Targeting Inflammation Driven by HMGB1. Front Immunol. 2020, 11, 484. [Google Scholar] [CrossRef] [PubMed]
- Du, O.; Wu, Y.J.; Li, M.Y.; Du, J.R. The role of HMGB1 in central nervous system (CNS) diseases: mechanisms and therapeutic perspectives. Cytokine 2026, 198, 157099. [Google Scholar] [CrossRef] [PubMed]
- Peng, K.; Fu, G.; Chen, L.; Xie, J.; Bao, K.; Li, J.P.; Luo, S.Z. CpG-A induces liquid-liquid phase separation of HMGB1 to activate the RAGE-mediated inflammatory pathway. Proc. Natl. Acad. Sci. U S A 2025, 122, e2505826122. [Google Scholar] [CrossRef] [PubMed]
- Shetty, S.; Hofstetter, J.; Battaglioni, S.; Ritz, D.; Hall, M.N. TORC1 phosphorylates and inhibits the ribosome preservation factor Stm1 to activate dormant ribosomes. EMBO J. 2023, 42, e112344. [Google Scholar] [CrossRef] [PubMed]
- Ji, Z.; Ablimit, A. SERBP1: A Multifunctional RNA-Binding Protein Linking Gene Expression, Cellular Metabolism, and Diseases. Cells 2025, 14. [Google Scholar] [CrossRef] [PubMed]
- Baudin, A.; Moreno-Romero, A.K.; Xu, X.; Selig, E.E.; Penalva, L.O.F.; Libich, D.S. Structural Characterization of the RNA-Binding Protein SERBP1 Reveals Intrinsic Disorder and Atypical RNA Binding Modes. Front Mol. Biosci. 2021, 8, 744707. [Google Scholar] [CrossRef] [PubMed]
- Anderson, E.N.; Gochenaur, L.; Singh, A.; Grant, R.; Patel, K.; Watkins, S.; Wu, J.Y.; Pandey, U.B. Traumatic injury induces stress granule formation and enhances motor dysfunctions in ALS/FTD models. Hum. Mol. Genet 2018, 27, 1366–1381. [Google Scholar] [CrossRef] [PubMed]
- Banani, S.F.; Lee, H.O.; Hyman, A.A.; Rosen, M.K. Biomolecular condensates: organizers of cellular biochemistry. Nat. Rev. Mol. Cell Biol. 2017, 18, 285–298. [Google Scholar] [CrossRef] [PubMed]
- Shao, W.; Bi, X.; Pan, Y.; Gao, B.; Wu, J.; Yin, Y.; Liu, Z.; Peng, M.; Zhang, W.; Jiang, X. Phase separation of RNA-binding protein promotes polymerase binding and transcription. Nat. Chem. Biol. 2022, 18, 70–80. [Google Scholar] [PubMed]
- Breunig, K.; Lei, X.; Montalbano, M.; Guardia, G.D.A.; Ostadrahimi, S.; Alers, V.; Kosti, A.; Chiou, J.; Klein, N.; Vinarov, C.; et al. SERBP1 interacts with PARP1 and is present in PARylation-dependent protein complexes regulating splicing, cell division, and ribosome biogenesis. Elife 2025, 13. [Google Scholar] [CrossRef]
- Tirupathi, S.J.; Uversky, V.N. Sticks with whips in neurodegenerative diseases: On the roles of intrinsic disorder in the (dis)function of cytoskeletal proteins. Adv. Protein Chem. Struct. Biol. 2026, 150, 29–118. [Google Scholar] [CrossRef] [PubMed]
- Yuan, A.; Rao, M.V.; Veeranna; Nixon, R.A. Neurofilaments at a glance. J. Cell Sci. 2012, 125, 3257–3263. [Google Scholar] [CrossRef] [PubMed]
- Delaby, C.; Bousiges, O.; Bouvier, D.; Fillee, C.; Fourier, A.; Mondesert, E.; Nezry, N.; Omar, S.; Quadrio, I.; Rucheton, B.; et al. Neurofilaments contribution in clinic: state of the art. Front Aging Neurosci. 2022, 14, 1034684. [Google Scholar] [CrossRef] [PubMed]
- Gafson, A.R.; Barthelemy, N.R.; Bomont, P.; Carare, R.O.; Durham, H.D.; Julien, J.P.; Kuhle, J.; Leppert, D.; Nixon, R.A.; Weller, R.O.; et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain 2020, 143, 1975–1998. [Google Scholar] [CrossRef] [PubMed]
- Gallo, G. The Axonal Actin Filament Cytoskeleton: Structure, Function, and Relevance to Injury and Degeneration. Mol. Neurobiol. 2024, 61, 5646–5664. [Google Scholar] [CrossRef] [PubMed]
- Mongan, K.L.; Sharma, T.P. Neuritin: a multifaceted neuroprotective factor with emerging applications for neurodegeneration. Front Neurosci. 2025, 19, 1698598. [Google Scholar] [CrossRef] [PubMed]
- Ding, E.A.; Kumar, S. Neurofilament Biophysics: From Structure to Biomechanics. Mol. Biol. Cell 2024, 35, re1. [Google Scholar] [CrossRef] [PubMed]
- Yao, J.J.; Zhao, Q.R.; Lu, J.M.; Mei, Y.A. Functions and the related signaling pathways of the neurotrophic factor neuritin. Acta Pharmacol. Sin. 2018, 39, 1414–1420. [Google Scholar] [CrossRef] [PubMed]
- Kazi, J.U.; Kabir, N.N.; Ronnstrand, L. Brain-Expressed X-linked (BEX) proteins in human cancers. Biochim Biophys. Acta 2015, 1856, 226–233. [Google Scholar] [CrossRef] [PubMed]
- Tong, X.; Xie, D.; Roth, W.; Reed, J.; Koeffler, H.P. NADE (p75NTR-associated cell death executor) suppresses cellular growth in vivo. Int. J. Oncol. 2003, 22, 1357–1362. [Google Scholar] [CrossRef] [PubMed]
- Chang, J.Y.; Li, L.; Lai, P.H. A major kinetic trap for the oxidative folding of human epidermal growth factor. J. Biol. Chem. 2001, 276, 4845–4852. [Google Scholar] [CrossRef] [PubMed]
- Kenchappa, R.S.; Zampieri, N.; Chao, M.V.; Barker, P.A.; Teng, H.K.; Hempstead, B.L.; Carter, B.D. Ligand-dependent cleavage of the P75 neurotrophin receptor is necessary for NRIF nuclear translocation and apoptosis in sympathetic neurons. Neuron 2006, 50, 219–232. [Google Scholar] [CrossRef] [PubMed]
- Green, D.R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 305, 626–629. [Google Scholar] [CrossRef] [PubMed]
- Shamas-Din, A.; Kale, J.; Leber, B.; Andrews, D.W. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 2013, 5, a008714. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N. Intrinsically disordered proteins from A to Z. Int. J. Biochem Cell Biol. 2011, 43, 1090–1103. [Google Scholar] [CrossRef] [PubMed]
- Dyson, H.J.; Wright, P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 2005, 6, 197–208. [Google Scholar] [CrossRef] [PubMed]
- do Amaral, M.J.; Araujo, T.S.; Diaz, N.C.; Accornero, F.; Polycarpo, C.R.; Cordeiro, Y.; Cabral, K.M.S.; Almeida, M.S. Phase Separation and Disorder-to-Order Transition of Human Brain Expressed X-Linked 3 (hBEX3) in the Presence of Small Fragments of tRNA. J. Mol. Biol. 2020, 432, 2319–2348. [Google Scholar] [CrossRef] [PubMed]
- Case, L.B.; Ditlev, J.A.; Rosen, M.K. Regulation of Transmembrane Signaling by Phase Separation. Annu Rev. Biophys. 2019, 48, 465–494. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Elbaum-Garfinkle, S.; Langdon, E.M.; Taylor, N.; Occhipinti, P.; Bridges, A.A.; Brangwynne, C.P.; Gladfelter, A.S. RNA Controls PolyQ Protein Phase Transitions. Mol. Cell 2015, 60, 220–230. [Google Scholar] [CrossRef] [PubMed]
- Remmelzwaal, S.; Geisler, F.; Stucchi, R.; van der Horst, S.; Pasolli, M.; Kroll, J.R.; Jarosinska, O.D.; Akhmanova, A.; Richardson, C.A.; Altelaar, M.; et al. BBLN-1 is essential for intermediate filament organization and apical membrane morphology. Curr. Biol. 2021, 31, 2334–2346 e2339. [Google Scholar] [CrossRef] [PubMed]
- Dorofeeva, A.; Shilenok, V.; Kobzeva, K.; Bushueva, O. Genes Encoding Heat-Resistant Obscure Proteins with Chaperone-Like Activities-Bbln and Serf2-Are Associated with Coronary Artery Disease Risk: A Pilot Study. Georgian Med. News 2025, 133–138.
- Shilenok, V.V.; Shilenok, I.V.; Soldatov, V.O.; Orlov, Y.L.; Kobzeva, K.A.; Deykin, A.V.; Bushueva, O.Y. Bioinformatic analysis of the regulatory potential of tagging SNPs provides evidence of the involvement of genes encoding the heat-resistant obscure (Hero) proteins in the pathogenesis of cardiovascular diseases. J. Integr. Bioinform. 2025, 22. [Google Scholar] [CrossRef] [PubMed]
- Tsuboyama, K.; Osaki, T.; Matsuura-Suzuki, E.; Kozuka-Hata, H.; Okada, Y.; Oyama, M.; Ikeuchi, Y.; Iwasaki, S.; Tomari, Y. A widespread family of heat-resistant obscure (Hero) proteins protect against protein instability and aggregation. PLoS Biol. 2020, 18, e3000632. [Google Scholar] [CrossRef] [PubMed]
- Skokowa, J.; Klimiankou, M.; Klimenkova, O.; Lan, D.; Gupta, K.; Hussein, K.; Carrizosa, E.; Kusnetsova, I.; Li, Z.; Sustmann, C.; et al. Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. Nat. Med. 2012, 18, 1550–1559. [Google Scholar] [CrossRef] [PubMed]
- Castro-Ochoa, K.F.; Guerrero-Fonseca, I.M.; Schnoor, M. Hematopoietic cell-specific lyn substrate (HCLS1 or HS1): A versatile actin-binding protein in leukocytes. J. Leukoc. Biol. 2019, 105, 881–890. [Google Scholar] [CrossRef] [PubMed]
- Uruno, T.; Zhang, P.; Liu, J.; Hao, J.J.; Zhan, X. Haematopoietic lineage cell-specific protein 1 (HS1) promotes actin-related protein (Arp) 2/3 complex-mediated actin polymerization. Biochem J. 2003, 371, 485–493. [Google Scholar] [CrossRef] [PubMed]
- Wakula, M.; Balcerak, A.; Rubel, T.; Chmielarczyk, M.; Konopinski, R.; Lyczek, F.; Grzybowska, E.A. The interactome of multifunctional HAX1 protein suggests its role in the regulation of energy metabolism, de-aggregation, cytoskeleton organization and RNA-processing. Biosci. Rep. 2020, 40. [Google Scholar] [CrossRef] [PubMed]
- Zhan, W.; Li, Z.; Zhang, J.; Liu, Y.; Liu, G.; Li, B.; Shen, R.; Jiang, Y.; Shang, W.; Gao, S.; et al. Energy stress promotes P-bodies formation via lysine-63-linked polyubiquitination of HAX1. EMBO J. 2024, 43, 2759–2788. [Google Scholar] [CrossRef] [PubMed]
- Scheffzek, K.; Shivalingaiah, G. Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions. Cold Spring Harb. Perspect. Med. 2019, 9. [Google Scholar] [CrossRef] [PubMed]
- Miotto, M.; Bo, L.; Ruocco, G.; Di Angelantonio, S.; Basilico, B. Missense mutations on SynGAP C2 domain impair membrane diffusion. Protein Sci. 2026, 35, e70574. [Google Scholar] [CrossRef] [PubMed]
- Cherra, S.J., 3rd; Lamb, R. Interactions between Ras and Rap signaling pathways during neurodevelopment in health and disease. Front Mol. Neurosci. 2024, 17, 1352731. [Google Scholar] [CrossRef] [PubMed]
- Llamosas, N.; Arora, V.; Vij, R.; Kilinc, M.; Bijoch, L.; Rojas, C.; Reich, A.; Sridharan, B.; Willems, E.; Piper, D.R.; et al. SYNGAP1 Controls the Maturation of Dendrites, Synaptic Function, and Network Activity in Developing Human Neurons. J. Neurosci. 2020, 40, 7980–7994. [Google Scholar] [CrossRef] [PubMed]
- Zeng, M.; Shang, Y.; Araki, Y.; Guo, T.; Huganir, R.L.; Zhang, M. Phase Transition in Postsynaptic Densities Underlies Formation of Synaptic Complexes and Synaptic Plasticity. Cell 2016, 166, 1163–1175 e1112. [Google Scholar] [CrossRef] [PubMed]
- Araki, Y.; Rajkovich, K.E.; Gerber, E.E.; Gamache, T.R.; Johnson, R.C.; Tran, T.H.N.; Liu, B.; Zhu, Q.; Hong, I.; Kirkwood, A.; et al. SynGAP regulates synaptic plasticity and cognition independently of its catalytic activity. Science 2024, 383, eadk1291. [Google Scholar] [CrossRef] [PubMed]
- Apweiler, R.; Bairoch, A.; Wu, C.H.; Barker, W.C.; Boeckmann, B.; Ferro, S.; Gasteiger, E.; Huang, H.; Lopez, R.; Magrane, M.; et al. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 2004, 32, D115–119. [Google Scholar] [CrossRef] [PubMed]
- Dayhoff, G.W., 2nd; Uversky, V.N. Rapid prediction and analysis of protein intrinsic disorder. Protein Sci. 2022, 31, e4496. [Google Scholar] [CrossRef] [PubMed]
- Aldadah, R.; Lekic, D.; Sabanovic, K.; Kovalenko, B.; Adilovic, M.; Hromic-Jahjefendic, A.; Uversky, V.N. Looking at bacterial cell poles from a liquid-liquid phase separation of intrinsically disordered proteins perspective. Curr. Res. Struct. Biol. 2025, 10, 100175. [Google Scholar] [CrossRef] [PubMed]
- Uversky, V.N. Analyzing IDPs in Interactomes. Methods Mol. Biol. 2020, 2141, 895–945. [Google Scholar] [CrossRef] [PubMed]
- Hatos, A.; Tosatto, S.C.E.; Vendruscolo, M.; Fuxreiter, M. FuzDrop on AlphaFold: visualizing the sequence-dependent propensity of liquid-liquid phase separation and aggregation of proteins. Nucleic Acids Res. 2022, 50, W337–W344. [Google Scholar] [CrossRef] [PubMed]
- Hardenberg, M.; Horvath, A.; Ambrus, V.; Fuxreiter, M.; Vendruscolo, M. Widespread occurrence of the droplet state of proteins in the human proteome. Proc. Natl. Acad. Sci. U S A 2020, 117, 33254–33262. [Google Scholar] [CrossRef] [PubMed]
- Vendruscolo, M.; Fuxreiter, M. FuzDrop: sequence-based prediction of the propensity of proteins for liquid-liquid phase separation and aggregation. Nat. Protoc. 2026, 21, 2016–2042. [Google Scholar] [CrossRef] [PubMed]
- Bertoni, D.; Tsenkov, M.; Magana, P.; Nair, S.; Pidruchna, I.; Querino Lima Afonso, M.; Midlik, A.; Paramval, U.; Lawal, D.; Tanweer, A.; et al. AlphaFold Protein Structure Database 2025: a redesigned interface and updated structural coverage. Nucleic Acids Res. 2026, 54, D358–D362. [Google Scholar] [CrossRef] [PubMed]
- Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Zidek, A.; Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021, 596, 583–589. [Google Scholar] [CrossRef] [PubMed]


















| Protein | UniProt ID | Length | Domain Organization | Involvement in TBI and neurodegeneration | Classification |
| Ras/Rap GTPase-activating protein SynGAP (SYNGAP1) | Q96PV0 | 1343 | Disordered (92-129, 373-394, 725-753, 781-805, 933-1017, 1033-1154, 1274-1343), PH domain (150-251), C2 domain (242-363), Ras-GAP domain (459-667), SH3-binding motif (785-815) | Critical in synapse function, associated with TBI-related epilepsy and developmental dysfunction | Downregulated |
| Ephrin type-A receptor 4 (EPHA4) | P54764 | 986 | Eph receptor ligand-binding domain (30-209), Fibronectin type-III domains (328-439, 440-537), protein kinase domain (621-882), SAM domain (911-975), PDZ-binding motif (984-986) | Receptor tyrosine kinase involved in axon guidance and plasticity, often upregulated as part of the glial scar response following TBI | Upregulated |
| Neurofilament medium polypeptide (NEFM) | P07197 | 916 | Disordered (1-51), head (2-104), IF rod (101-412), coiled-coil regions (105-136, 150-248, 266-287, 292-412), tail (413-916), tandem repeates (614-626, 627-639, 649-652, 653-665m 666-678, 679-691) | Released following axonal injury, serving as markers of axonal damage and chronic neurodegeneration | Downregulated |
| Semaphorin-4D (SEMA4D) | Q92854 | 862 | Sema domain (22-500), PSI domain (521-551), IG-like C2-type domain (554-636), disordered (794-837¬) | Involved in regulating neuroinflammatory responses, particularly microglial activation in injury | Upregulated |
| Amyloid-beta precursor protein (APP) | P05067 | 770 | GFLD subdomain (28-123), E1 domauin (28-189), CuBD subdomain (131-189), disordered (194-284), BPTI/Kunitz inhibitor domain (291-341), OX-2 motif (344-365), E2 domain (374-565), heparin-binding region (391-423, 491-522), collagen binding region (523-540), PSEN1 binding region (695-722), basolateral sorting signal motif (724-734), interaction with Go-α (732-751), KIF5B bonding region (756-770), YENPXY motif (757-762) | Accumulates in damaged axons and is a major component of plaques that form as a secondary consequence of TBI, contributing to post-traumatic neurodegeneration | Upregulated |
| Microtubule-associated protein tau (MAPT) | P10636 | 758 | Disordered (1-573), microtubule-binding domain (561-685), tubulin-binding repeats (561-591, 592-622, 623-653, 654-685), disordered (714-734) | Released into the blood after severe TBI, with higher levels correlating with poorer long-term outcomes and chronic neuroplasticity change | Mixed |
| Disks large homolog 4 (DLG4) | P78352 | 724 | Disordered (15-35), PDZ domains (65-151, 160-246, 313-393), SH3 domain (428-498), guanylate kinase-like domain (534-798) | Released into cerebrospinal fluid (CSF) following acute traumatic damage, acting as indicators of synaptic | Downregulated |
| Neurofilament light polypeptide (NEFL) | P07196 | 543 | Head (2-92), IF rod (90-400), coiled coil domains (93-124, 138-234,235-252, 253-271, 281-396), tail subdomain A (397-443), tail (397-543), tail subdomain B (444-543) | Released following axonal injury, serving as markers of axonal damage and chronic neurodegeneration | Mixed |
| RNA-binding protein FUS (FUS) | P35637 | 526 | Disordered (1-286, 375-424, 444-526), RRM domain (285-371), RanBP2-type zinc finger (422-453) | An RNA-binding protein that can mislocalize and form aggregates after injury | Upregulated |
| Hematopoietic cell-specific Lyn substrate 1 (HCLS1) |
P14317 | 486 | HAX-1-binding region (27-66), contactin repeats (79-115. 116-152, 153-189, 190-212), DISORDERED (243-419), sh3 DOMAIN (428-486) | Associated with remodeling of the cytoskeleton in immune cells, likely involved in the neuroinflammatory response | Upregulated |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha (CAMK2A) | Q9UQM7 | 478 | protein kinase domain (13-271), calmodulin-binding region (290-300), BAALC-binding region (310-320), disordered (314-341) | Involved in synaptic plasticity and memory formation, often dysfunctional following TBI-induced excitotoxicity | Downregulated |
| TAR DNA-binding protein 43 (TDP43) | Q13148 | 414 | Nuclear localization signal (82-98), nuclear export signal (239-250), RNA recognition motifs (RRMs; 104-200, 191-262), disordered (261-303, 341-373) | Misfolds and aggregates following TBI, contributing to long-term neurodegeneration, including CTE | Upregulated |
| Pleckstrin (PLEK) | P08567 | 350 | PH1 domain (4-101), DEP domain (136-221), OH2 domain (244-347) | Part of kinase signaling pathways in platelet and neuronal activity | Upregulated |
| SERPINE1 mRNA-binding protein 1 (SERBP1) | Q8NC51 | 408 | Disordered (33-292), N-terminal Habp4-like domains (5–152 and 189–314), RG/RGG (arginine/glycine-rich) repeat sequences (163–182 and 366–381), disordered (328-408) | Shows altered methylation patterns in the blood of individuals with TBI | Mixed |
| High mobility group protein B1 (HMGB1) | P09429 | 215 | Interaction with HAVCR2 (1-87), LPS binding regions (3-15, 80-96), nuclear localization signals (27-43, 178-184), disordered (76-95, 161-215), cytokine-stimulating activity (89-108), binding to AGER/RAGE | A mediator of neuroinflammation, consistently upregulated after TBI, contributing to blood-brain barrier dysfunction and secondary neurodegeneration | Upregulated |
| Synaptosomal-associated protein 25 (SNAP25) | P60880 | 206 | Disordered (1-23), interaction with CENPF (1-75), t-SNARE coiled-coil homology domains (18-92, 140-202), interaction with ZDHHC17 (111-120) | Released into cerebrospinal fluid (CSF) following acute traumatic damage, acting as indicators of synaptic | Downregulated |
| C9orf58; Allograft inflammatory factor 1-like (AIF1L); Ionized calcium-binding adapter molecule 2 (IBA2) | Q9BQI0 | 150 | EF-hand motifs (47-82 and 83-117), disordered (129-150) | Known functions in actin filament regulation, cellular morphology, and actin-related membrane reorganization suggest involvement in TBI; Aids the movement of immune cells to the site of injury; Participates in the remodeling of the cytoskeleton during glial scar formation or neuronal repair; Acts as a well-established marker of microglial activation | Mixed |
| Neuritin (NRN1) | Q9NPD7 | 142 | Signal (1-27), propeptide (117-142) | Involved in neurite outgrowth and neuronal remodeling after injury | Downregulated |
| α-Synuclein (SNCA) | P37840 | 140 | Tandem repeats (20-67:20-50, 31-41. 42-56, 57-67), non-Aβ component of Alzheimer’s disease amyloid (NAC; 61-95), interaction with SERF1A (111-140) | Misfolds and aggregates following TBI, contributing to long-term neurodegeneration, including CTE | Upregulated |
| Brain-expressed X-linked protein 3 (BEX3) | Q00994 | 111 | Disordered (1-63), interaction with p75NTR/NGFR (98-93), interaction with 14-3-3 epsilon (68-11), nuclear export signal (77-87), His cluster 100-104 | Involved in p75NTR-mediated neuronal death (apoptosis) following traumatic injuries | Mixed |
| Apolipoprotein C-II (APOC2) | P02655 | 101 | O-glycosylated region (23-38), lipid binding region (66-74), lipoprotein lipase cofactor (78-101) | Known for involvement in lipid metabolism, altered levels indicate lipid dysfunction after injury | Upregulated |
| S100 calcium-binding protein B (S100B) | P04271 | 92 | EF hand domains (13-48, 49-84) | A well-established glial-derived serum biomarker for TBI, used for assessing the risk of intracranial lesions | Upregulated |
| C9orf16; Bublin coiled-coil protein (BBLN) | Q9BUW7 | 83 | Disordered (1-24), coiled-coil domain (25-74) | Play roles in brain injuries associated with ischemic stroke and neurodegeneration; May serve as a neuroprotective chaperone and a potential biomarker in TBI | Mixed |
| Small EDRK-rich factor 2 (SERF2) | P84101 | 59 | Disordered (1-59) | Promotes protein misfolding and amyloid aggregation, linking it to the aggregation pathways of SNCA and MAPT following trauma | Mixed |
| Protein | UniProt ID | Length | ADSVSL2 | PPDRVSL2 | MoRFs | pLLPS | DPRs | Average pLDDT |
| FUS | P35637 | 526 | 0.8894 | 90.68% | 1-19, 33-61, 75-83, 89-103, 111-165, 175-196, 205-212, 231-240, 257-268, 285-312, 347-375, 423-428, 432-445, 478-486, 489-512 | 0.9999 | 1-294, 360-437, 443-526 | 53.59 |
| HMGB1 | P09429 | 215 | 0.8511 | 91.16% | 13-23, 37-44, 100-110, 121-133, 154-165 | 0.8945 | 1-14, 74-101, 155-215 | 76.81 |
| HCLS1 | P14317 | 486 | 0.7326 | 87.45% | 1-12, 52-58, 81-88, 98-106, 192-201, 208-213, 227-246, 278-307, 321-364, 375-387, 391-440 | 0.9962 | 1-24, 70-102, 111-165, 172-184, 189-200, 225-434 | 63.59 |
| SNCA | P37840 | 140 | 0.7199 | 90.71% | 87-96, 111-140 | 0.6249 | 101-140 | 75.19 |
| TDP43 | Q13148 | 414 | 0.5866 | 57.25% | 28-35, 245-255, 311-342, 380-387, 397-402 | 0.8981 | 251-414 | 65.19 |
| S100B | P04271 | 92 | 0.5099 | 63.04% | 8-15 | 0.1158 | Not found | 91.44 |
| APP | P05067 | 770 | 0.4982 | 47.53% | 181-190, 205-243, 251-275, 283-291, 301-322, 336-346, 391-396, 426-437, 471-478, 491-497, 545-550, 606-626 | 0.7463 | 188-216, 230-285, 353-373, 437-451, 624-657 | 67.38 |
| APOC2 | P02655 | 101 | 0.4577 | 45.54% | Not found | 0.1357 | 21-33 | 65.88 |
| Protein | UniProt ID | Length | ADSVSL2 | PPDRVSL2 | MoRFs | pLLPS | DPRs | Average pLDDT |
| NEFM | P07197 | 916 | 0.8292 | 88.32% | 1-8, 56-69, 110-122, 290-299, 390-401, 449-457, 469-486, 504-520, 543-551, 575-580, 594-609, 740-757, 796-806, 829-836, 853-858, 869-877 | 0.9977 | 1-51, 61-106, 265-290, 458-866 | 57.19 |
| SNAP25 | P60880 | 206 | 0.6905 | 78.16% | 43-50, 81-95, 128-135, 153-167, 199-206 | 0.2529 | 1-28, 196-206 | 83.38 |
| SYNGAP1 | Q96PV0 | 1343 | 0.6649 | 66.34% | 46-68, 81-87, 113-140, 155-163, 345-350, 751-786, 802-825, 833-848, 859-867, 896-939, 959-966-961-1137, 1148-1184, 1231-1240, 1258-12731288-1320, 1328-1343 | 0.9986 | 1-44, 87-134, 141-156, 177-194, 295-305, 331-343, 365-400, 716-756, 770-829, 849-1016, 1027-1155, 1237-1255, 1272-1343 | 59.22 |
| DLG4 | P78352 | 724 | 0.4186 | 33.29% | 43-54, 74-79, 94-99, 236-241336-343531-541 | 0.6983 | 17-37, 79-91, 253-265, 276-294, 412-429, 497-525 | 77.56 |
| CAMK2A | Q9UQM7 | 478 | 0.3594 | 19.04% | 289-294, 299-310, 351-359, 428-435 | 0.2248 | 309-348 | 85.81 |
| NRN1 | Q9NPD7 | 142 | 0.2844 | 12.68% | Not found | 0.1490 | Not found | 78.56 |
| Protein | UniProt ID | Length | ADSVSL2 | PPDRVSL2 | MoRFs | pLLPS | DPRs | Average pLDDT |
| SERF2 | P84101_C P84101_L |
59 170 |
0.9906 0.7757 |
100.00% 98.82% |
1-50 1-61 |
0.9942 0.885 |
1-59 1-37, 75-95, 158-170 |
81.38 57.12 |
| MAPT | P10636 | 758 | 0.8602 | 99.08% | 1-56, 58-167, 177-214, 216-283, 288-334, 337-351, 357-386, 393-414, 419-492, 508-519, 525-532, 539-580, 589-608, 622-643, 663-576, 707-715, 741-758 | 0.9985 | 1-300, 309-589, 608-622, 719-739 | 49.22 |
| SERBP1 | Q8NC51 | 408 | 0.8413 | 96.32% | 1-34, 47-71, 81-90, 98-111, 116-125, 149-169, 179-187, 199-211, 230-252, 288-309, 317-329, 337-365, 390-408 | 0.9972 | 29-101, 105-236, 246-279, 359-408 | 54.16 |
| BEX3 | Q00994 | 111 | 0.8194 | 100.00% | 1-9, 41-55, 84-95 | 0.9751 | 1-47, 55-65, 92-11 | 66.62 |
| C9orf16 | Q9BUW7 | 83 | 0.7335 | 84.34% | 7-14, 22-49, 51-62, 67-77 | 0.9307 | 1-24, 67-83 | 80.31 |
| NEFL | P07196 | 543 | 0.7306 | 82.69% | 381-388, 422-466, 488-501, 530-539 | 0.7555 | 1-12, 409-448, 455-543 | 73.06 |
| C9orf58 | Q9BQI0 | 150 | 0.6315 | 80.00% | 116-126 | 0.3061 | 1-15, 126-150 | 84.12 |
| Protein set | Areas in the ADS vs. PPIDR plot | Quadrants in the ΔCH-ΔCDF plot | |||||||
| Blue | Cyan | Pink | Light pink | Red | Q1 | Q2 | Q3 | Q4 | |
| TBIome | 0.00 | 0.00 | 20.83 | 12.50 | 66.67 | 37.50 | 12.50 | 45.83 | 4.17 |
| Interactome of TBIome | 0.00 | 1.17 | 32.10 | 25.49 | 41.24 | 49.61 | 26.07 | 21.40 | 2.92 |
| Brainome | 0.00 | 3.06 | 35.72 | 25.10 | 36.12 | 59.73 | 30.14 | 8.91 | 1.22 |
| Proteome | 0.41 | 5.07 | 33.67 | 21.01 | 39.84 | 59.13 | 25.48 | 12.31 | 3.08 |
| Functional term | Number of statistically significantly enriched functional terms | ||
| TBIome | TBIome interactome | Fold increase | |
| Biological Process (Gene Ontology) | 129 | 1585 | 12.29 |
| Molecular Function (Gene Ontology) | 5 | 212 | 42.40 |
| Cellular Component (Gene Ontology) | 30 | 292 | 9.73 |
| Local Network Cluster (STRING) | 0 | 116 | |
| KEGG Pathways | 0 | 154 | |
| Reactome Pathways | 12 | 497 | 41.42 |
| Disease-gene Associations (DISEASES) | 20 | 86 | 4.30 |
| Tissue Expression (TISSUES) | 39 | 139 | 3.56 |
| Subcellular Localization (COMPARTMENTS) | 35 | 268 | 7.66 |
| Human Phenotype (Monarch) | 55 | 647 | 11.76 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).